Krystal Biotech, Inc.
KRYSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Krystal Biotech, Inc. focuses on Biotechnology services and products. Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United. The $9.22B market capitalization puts KRYS squarely in mid-cap range for its industry. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Market Cap
$9.22B
Beta
0.50
P/E (TTM)
40.14
P/E (Fwd)
34.80
EPS (TTM)
$7.76
EPS (Fwd)
$8.95
ROE
20.1%
ROA
9.4%
Cash
$845.6M
Total Debt
$8.9M
Free CF
$151.7M
52W Change
67.4%
Annual Financials
Cash vs Debt
Where KRYS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, KRYS finished 0.69% above its 150-day moving average ($318.05) and 4.71% above its 200-day moving average ($305.84). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KRYS overbought or oversold?
At the October 20, 2026 close, KRYS's RSI(14) was 40.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $845.6M in cash comfortably exceeding the $8.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $151.7M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 20.1%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 9.4% suggests reasonable efficiency in deploying the company's asset base.
The relatively low beta of 0.50 suggests KRYS is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Krystal Biotech, Inc. and its sector.